Vnitr Lek 2014, 60(12):1081-1085

Renal denervation in patients with resistant hypertension: is it still possible to resuscitate?

Miloš Táborský1,*, Marcela Schejbalová2
1 I. interní klinika kardiologická LF UP a FN Olomouc, přednosta prof. MUDr. Miloš Táborský, CSc., FESC, MBA
2 Kardiologická ambulance, Heart Solution, s.r.o., Praha 5, vedoucí lékař prof. MUDr. Miloš Táborský, CSc., FESC, MBA

Transcatheter renal denervation (RDN) has been markedly applied and developed in clinical practice in past five years and not only for patients with resistant hypertension. The issue that more than 50% patients with so-called resistant hypertension are in fact patients without adherence to this type of mediation has not been resolved in RDN trials till now. The study Symplicity HTN-3 showed no differences in blood pressure change between the patients with RDN and group of patients after false procedure who continued in their drug therapy. Future of RDN is more than questionable and there is a need to return to animal studies that will verify the real effectiveness of RDN, subsequently, will redefine population of patients indicated for RDN and confirm the applicability of newly developed techniques.

Keywords: renal denervation; renal sympathetic innervation; resistant hypertension

Received: November 9, 2014; Accepted: November 13, 2014; Published: December 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Táborský M, Schejbalová M. Renal denervation in patients with resistant hypertension: is it still possible to resuscitate? Vnitr Lek. 2014;60(12):1081-1085.
Download citation

References

  1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303(20): 2043-2050. Go to original source... Go to PubMed...
  2. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125(13): 1594-1956. Go to original source... Go to PubMed...
  3. Gonzalez O, Iriarte G, Rico E. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatorg B Analyt Technol Biomed Life Sci 2010; 878(28): 2685-2692. Go to original source... Go to PubMed...
  4. Page IH, Heuer GJ. The effect of renal denervationon the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest 1935; 14(1): 27-30. Go to original source... Go to PubMed...
  5. Grimson KS, Orgain ES, Anderson B et al. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 1949; 129(6): 850-871. Go to original source...
  6. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25(4 Pt 2): 878-882. Go to original source... Go to PubMed...
  7. Masuo K, Lambert GW, Esler MD et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 2010; 33(6): 521-528. Go to original source... Go to PubMed...
  8. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373(9671): 1275-1281. Go to original source... Go to PubMed...
  9. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment resistant hypertension (the SYMPLICITY HTN-2Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903-1909. Go to original source... Go to PubMed...
  10. Davis MI, Filion KB, Zhangg D et al. Efectiveness of renal denervation therapy for resistent hypertension. A systematic review and meta-analysis. J Am Coll Cardiol 2013; 62(3): 231-241. Go to original source... Go to PubMed...
  11. Bhatt DL, Kandzari DE, O'Neill WW et al. A controlled trial of renal denervation for resistant hypertension. New Engl J Med 2014; 370(15): 1393-1401. Go to original source... Go to PubMed...
  12. Bakris GL, Townsend RR, Liu M et al. SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014; 64(11): 1071-1078. Go to original source... Go to PubMed...
  13. Kandzari DE. Symplicity HTN-3: insights from the subgroup analysis. Paper presented at the EuroPCR 2014 Hot Line Session. May 22, 2014. Paris, France.
  14. Bhatt DL, Kandzari DE, O'Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393-1401. Go to original source... Go to PubMed...
  15. Toušek P, Widimský J, jr, Rosa J et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. Cor et Vasa 2014; 36: e235-e239. Dostupné z WWW: <http://www.sciencedirect.com/science/article/pii/S0010865014000435>. Go to original source...
  16. Tzafriri AR, Mahfoud F, Keating JH et al. Innervation patterns may limit response to endovascularrenal denervation. J Am Coll Cardiol 2014; 64(11): 1079-1087. Go to original source... Go to PubMed...
  17. Goldschmeding R, Vink A, Weggemans C et al. Limited destruction of renal nerves after catheter based renal denervation: results of a human case study. Nephrol Dial Transplant 2014; 29(8): 1608-1610. Go to original source... Go to PubMed...
  18. Persu A, Jin Y, Baelen M et al. Eligibility for renal denervation. Experience at 11 european expert centers. Hypertension 2014; 63(6): 1319-1325. Go to original source... Go to PubMed...
  19. Václavík J, Sedlák R, Plachý M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57(6): 1069-1075. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.